

Status of Specific Methods

List class	Targets	Matrix (sample type)	Mandatory by all Laboratories	Applied to all samples
Steroid esters (S1.1)	Testosterone, Nandrolone, etc	serum ¹ plasma ² capillary blood ³	No	No - upon TA request
GC/C/IRMS	Markers urinary steroid profile (S1.1)	urine	Yes	Yes (if needed as a confirmation test or if requested by TA/RMA/APMU/WADA)
	Epiandrosterone (EpiA_)	urine	No	May be used as an additional target compound (in the sulfoconjugated fraction) to determine the administration of testosterone or its precursors
	19-NA (S1.1), Boldenone & Boldenone Metabolites (S1.1), Formestane (S4.1), 6α-hydroxy-androstenedione (S1.1)	urine	Yes (presence) No (IRMS confirmation)	Presence tested for in all samples, but if GC/C/IRMS confirmation needed, subcontract to another laboratory if no capacity
ERAs (S2.1.1)	recEPO, dEPO, CERA, EPO-Fc	urine serum ¹ plasma ² capillary blood ³	Yes	No - upon TA request
HIF activating agents (S2.1.2)	Daprodustat, Desidustat, IOX2, Molidustat, Roxadustat, Vadadustat	urine capillary blood ³	Yes	Yes
	Cobalt Xenon	urine	No	No - upon TA request
Transforming growth factor beta (TGF-β) signalling inhibitors (S2.1.4)	luspatercept sotatercept	urine serum ¹ plasma ²	No	No - upon TA request
Intact hCG (S2.2.1)	Screening (intact or total hCG)	urine	Yes	Yes
	Confirmation (intact hCG, different from screening assay)	urine	No	Subcontract to another laboratory if no capacity
LH (S2.2.1)		urine	No	No (Laboratories with capacity do test all urine samples)
Corticotrophins (S2.2.2)	Corticotrophin	urine	No	No - upon Testing Authority (TA) request
hGH (S2.2.3)	hGH Isoforms	serum ¹	Yes	No - upon Testing Authority (TA) request
	hGH Biomarkers (IGF-I, P-III-NP)	serum ¹	No	No - upon TA request
	Endocrine Passport (IGF-I, P-III-NP)	serum ¹	No	No - upon TA request
Small peptides	GnRF (S2.2.1) AOD-9604, hGH 176-191 (S2.2.3) GHS (2.2.4) GHRP (2.2.4)	urine capillary blood ³	Yes	No - upon TA request. GnRH also done if needed to confirm elevated LH findings. Some laboratories apply small peptides method to all samples (agreement with TA).

¹ Obtained after centrifugation of venous blood collected in serum tubes (blood sample)

² Obtained after centrifugation of venous blood collected in EDTA tubes (blood ABP sample)

³ Obtained using dried blood spot (DBS) sample collection devices

List class	Targets	Matrix (sample type)	Mandatory by all Laboratories	Applied to all samples
	TB-500 (S2.3) Desmopressin, Felypressin (S5)			
Large peptides	GHRH (S2.2.3) IGF-I analogues (S2.3) Insulins (S4.4.2)	urine serum ¹ plasma ² capillary blood ³	No	No - upon TA request
Anti-activin receptor IIB antibodies (S4.3) Myostatin Inhibitors (S4.3)	e.g., Bimagrumab	urine serum ¹ plasma ²	No	No - upon TA request
Blood Manipulation (M1.1)	Homologous Blood Transfusion (HBT) - Minor Red Blood Cell Antigens	whole blood ⁴	No	No - upon TA request
Artificially enhancing the uptake, transport or delivery of oxygen (M1.2)	HBOCs (M1.2)	serum ¹ plasma ² capillary blood ³ whole blood ⁴	No	No - upon TA request
	Myo-inositol trispyrophosphate (ITPP)	urine serum ¹ plasma ²	No	No - upon TA request
DNA analysis (M2.1)		urine serum ¹ plasma ² whole blood ⁴	No	No - upon TA request if suspicious of sample switch or upon WADA request if needed as part of investigation into recEPO finding
Proteases (M2.1)		urine serum ¹ plasma ²	No	No - upon TA request if suspicious of tampering
Gene Doping (M3.1)	cDNA transfer (e.g., EPO) siRNA (e.g., myostatin siRNA)	capillary blood ³ whole blood ⁴	No	No - upon TA request
Hematological Module of ABP	Blood Markers of ABP	whole blood ⁴	No	No – upon collection of ABP samples
Blood Markers of the Steroidal Module of ABP	Testosterone, Androstenedione (S1.1)	serum ¹	No	No - upon TA request

⁴ Obtained using EDTA tubes (blood ABP samples)